Medexus Pharmaceuticals (TSE:MDP) Price Target Raised to C$6.25

Medexus Pharmaceuticals (TSE:MDP) had its target price increased by Ventum Financial from C$5.00 to C$6.25 in a research note issued to investors on Thursday morning,BayStreet.CA reports. They currently have a buy rating on the stock.

A number of other research firms have also recently weighed in on MDP. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Stifel Nicolaus raised their price target on shares of Medexus Pharmaceuticals from C$4.50 to C$6.00 in a research note on Thursday. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective on the stock in a research note on Wednesday, January 8th. Finally, Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. Two research analysts have rated the stock with a buy rating and five have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Strong Buy” and an average target price of C$6.13.

Medexus Pharmaceuticals Trading Down 0.2 %

Shares of Medexus Pharmaceuticals stock opened at C$3.99 on Thursday. The firm’s 50 day moving average is C$3.41 and its 200 day moving average is C$2.77. The firm has a market capitalization of C$97.87 million, a PE ratio of 79.80 and a beta of 1.96. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.